Effect of Neoadjuvant Therapy on Breast Cancer Biomarker Profile

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Jul 20

PMID 32682413

Citations 12

Authors

Laura Rey-Vargas

Juan Carlos Mejia-Henao

Maria Carolina Sanabria-Salas

Silvia J Serrano-Gomez

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer clinical management requires the assessment of hormone receptors (estrogen (ER) and progesterone receptor (PR)), human epidermal growth factor receptor 2 (HER2) and cellular proliferation index Ki67, by immunohistochemistry (IHC), in order to choose and guide therapy according to tumor biology. Many studies have reported contradictory results regarding changes in the biomarker profile after neoadjuvant therapy (NAT). Given its clinical implications for the disease management, we aimed to analyze changes in ER, PR, HER2, and Ki67 expression in paired core-needle biopsies and surgical samples in breast cancer patients that had either been treated or not with NAT.

Methods: We included 139 patients with confirmed diagnosis of invasive ductal breast carcinoma from the Colombian National Cancer Institute. Variation in biomarker profile were assessed according to NAT administration (NAT and no-NAT treated cases) and NAT scheme (hormonal, cytotoxic, cytotoxic + trastuzumab, combined). Chi-squared and Wilcoxon signed-rank test were used to identify changes in biomarker status and percentage expression, respectively, in the corresponding groups.

Results: We did not find any significant variations in biomarker status or expression values in the no-NAT group. In cases previously treated with NAT, we did find a statistically significant decrease in Ki67 (p < 0.001) and PR (p = 0.02605) expression. When changes were evaluated according to NAT scheme, we found a significant decrease in both Ki67 status (p = 0.02977) and its expression values (p < 0.001) in cases that received the cytotoxic treatment.

Conclusions: Our results suggest that PR and Ki67 expression can be altered by NAT administration, whereas cases not previously treated with NAT do not present IHC biomarker profile variations. The re-evaluation of these two biomarkers after NAT could provide valuable information regarding treatment response and prognosis for breast cancer patients.

Citing Articles

Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma.

Korpinen K, Autere T, Tuominen J, Loyttyniemi E, Eigeliene N, Talvinen K Breast Cancer Res Treat. 2024; .

PMID: 39739270 DOI: 10.1007/s10549-024-07584-4.

Impact of Neoadjuvant Chemotherapy (NAC) on Biomarker Expression in Breast Cancer.

Lee S, Kim J, Lee S, Hwang C, Lee H, Kim K Medicina (Kaunas). 2024; 60(5).

PMID: 38792920 PMC: 11123214. DOI: 10.3390/medicina60050737.

Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.

Wang M, Wei Z, Kong J, Zhao H Diagn Pathol. 2024; 19(1):53.

PMID: 38509525 PMC: 10953119. DOI: 10.1186/s13000-024-01451-y.

Multiplex electrochemical sensing platforms for the detection of breast cancer biomarkers.

OBrien C, Khor C, Ardalan S, Ignaszak A Front Med Technol. 2024; 6:1360510.

PMID: 38425422 PMC: 10902167. DOI: 10.3389/fmedt.2024.1360510.

Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.

Yi X, Hu S, Ma M, Huang D, Zhang Y Clin Transl Oncol. 2023; 26(4):880-890.

PMID: 37702827 DOI: 10.1007/s12094-023-03318-y.

References

Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E . Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008; 28(3B):1797-804. View

Dede D, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y . Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON. 2013; 18(1):57-63. View

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, AHern R . Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007; 99(2):167-70. DOI: 10.1093/jnci/djk020. View

Hayashi N, Takahashi Y, Matsuda N, Tsunoda H, Yoshida A, Suzuki K . The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype. Clin Breast Cancer. 2017; 18(2):e219-e229. DOI: 10.1016/j.clbc.2017.09.013. View

Enomoto Y, Morimoto T, Nishimukai A, Higuchi T, Yanai A, Miyagawa Y . Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. Int J Clin Oncol. 2015; 21(2):254-261. DOI: 10.1007/s10147-015-0897-1. View

Kroigard A, Larsen M, Laenkholm A, Knoop A, Jensen J, Bak M . Clonal expansion and linear genome evolution through breast cancer progression from pre-invasive stages to asynchronous metastasis. Oncotarget. 2015; 6(8):5634-49. PMC: 4467391. DOI: 10.18632/oncotarget.3111. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Liu S, Melstrom L, Yao K, Russell C, Sener S . Neoadjuvant therapy for breast cancer. J Surg Oncol. 2010; 101(4):283-91. DOI: 10.1002/jso.21446. View

10.

Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell G, Acar A . The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. Clin Cancer Res. 2018; 24(19):4763-4770. PMC: 6296441. DOI: 10.1158/1078-0432.CCR-17-3374. View

11.

Eroles P, Bosch A, Perez-Fidalgo J, Lluch A . Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2011; 38(6):698-707. DOI: 10.1016/j.ctrv.2011.11.005. View

12.

Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier M . Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist. 2008; 13(12):1235-45. DOI: 10.1634/theoncologist.2008-0073. View

13.

Romero Q, Bendahl P, Klintman M, Loman N, Ingvar C, Ryden L . Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer. 2011; 11:341. PMC: 3163632. DOI: 10.1186/1471-2407-11-341. View

14.

Kang Y, Lee H, Kim Y, Han J, Kim Y, Yoo T . Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer. J Oncol. 2020; 2019:7386734. PMC: 6949686. DOI: 10.1155/2019/7386734. View

15.

Li C, Fan H, Xiang Q, Xu L, Zhang Z, Liu Q . Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019; 178(3):497-504. DOI: 10.1007/s10549-019-05421-7. View

16.

Tural D, Karaca M, Zirtiloglu A, M Hacioglu B, Sendur M, Ozet A . Receptor discordances after neoadjuvant chemotherapy and their effects on survival. J BUON. 2019; 24(1):20-25. View

17.

Xian Z, Quinones A, Tozbikian G, Zynger D . Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?. Hum Pathol. 2017; 62:215-221. DOI: 10.1016/j.humpath.2016.12.019. View

18.

Rye I, Trinh A, Saetersdal A, Nebdal D, Lingjaerde O, Almendro V . Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol. 2018; 12(11):1838-1855. PMC: 6210052. DOI: 10.1002/1878-0261.12375. View

19.

Lim S, Lee M, Park I, You J, Nam B, Kim B . Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. Cancer Res Treat. 2015; 48(1):133-41. PMC: 4720061. DOI: 10.4143/crt.2014.262. View

20.

Knutsvik G, Stefansson I, Aziz S, Arnes J, Eide J, Collett K . Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One. 2014; 9(11):e112121. PMC: 4223011. DOI: 10.1371/journal.pone.0112121. View